The above trials have provided proof of concept that neoadjuvant immunotherapy and/or BRAF/MEK inhibition can lead to clinical and pathologic response before surgery and potentially improve long term outcomes for patients with resectable melanoma. The gene discussed is MAP2K7; the disease is melanoma.